SELLAS Life Sciences Group, Inc.
SLS
$1.56
-$0.05-3.11%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.84M | 13.52M | 13.02M | 13.60M | 14.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.03M | 32.61M | 32.77M | 34.80M | 36.23M |
| Operating Income | -29.03M | -32.61M | -32.77M | -34.80M | -36.23M |
| Income Before Tax | -27.13M | -30.88M | -32.28M | -34.44M | -35.81M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -27.13 | -30.88 | -32.28 | -34.44 | -35.81 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.13M | -30.88M | -32.28M | -34.44M | -35.81M |
| EBIT | -29.03M | -32.61M | -32.77M | -34.80M | -36.23M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.39 | -0.54 | -0.71 | -0.93 | -1.12 |
| Normalized Basic EPS | -0.25 | -0.35 | -0.44 | -0.58 | -0.70 |
| EPS Diluted | -0.39 | -0.54 | -0.71 | -0.93 | -1.12 |
| Normalized Diluted EPS | -0.25 | -0.35 | -0.44 | -0.58 | -0.70 |
| Average Basic Shares Outstanding | 287.63M | 244.69M | 201.50M | 161.60M | 132.32M |
| Average Diluted Shares Outstanding | 287.63M | 244.69M | 201.50M | 161.60M | 132.32M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |